221 results about "Type 2 diabetes" patented technology

The invention relates to the technical field of medical information processing, in particular to a type 2 diabetes precise typing and dynamic treatment system which comprises a clinical feature extraction module, a metabolism dynamic modeling module, a precise typing module, a treatment parameter generation module and a dynamic treatment output module. Wherein the clinical feature extraction module is used for collecting a multi-dimensional clinical data set of a patient for continuous 14 days; the metabolism dynamic modeling module is used for extracting blood glucose fluctuation characteristics and pancreas islet function compensation characteristics; the precise typing module is used for dividing metabolism-driven subtypes to which the patients belong through a clustering algorithm; the treatment parameter generation module is used for mapping a subtype-treatment rule base and outputting a matched personalized treatment parameter combination; and the dynamic treatment output module outputs a dynamic treatment scheme. According to the invention, through a dynamic treatment mechanism based on typing, linkage control of individual difference identification and real-time adjustment of the medication scheme of the type 2 diabetes patients is realized, and the accuracy and adaptability of treatment are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-propane diamine or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating diabetes. Experimental results show that 1, 3-propane diamine can obviously improve random blood glucose and fasting blood glucose of mice with type 2 diabetes mellitus, and 1, 3-propane diamine can obviously improve insulin resistance of model mice. According to the application, 1, 3-propane diamine is used for improving the blood sugar of patients with type 2 diabetes for the first time, an ideal treatment effect is achieved, a new treatment choice is provided for improving the blood sugar level through clinical application of 1, 3-propane diamine, and the application has extremely high application value and social benefits.

The invention discloses a traditional Chinese medicine composition for treating type 2 diabetes and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 11-15 parts of radix acanthopanacis semticosi, 5-15 parts of male silkworm moth, 7-17 parts of white ginseng, 5-11 parts of rhizoma polygoni cuspidati, 15-25 parts of rhizoma coptidis, 1-5 parts of cortex cinnamomi, 11-15 parts of fructus ligustri lucidi, 11-15 parts of common fenugreek seed, 7-17 parts of lithocarpus litseifolius, 3-7 parts of raw radix astragali and 1-3 parts of wild lucid ganoderma. , 3-9 parts of tribulus terrestris and 11-17 parts of nigella nigra seeds. The traditional Chinese medicine composition has the effect of balancing and stabilizing blood sugar, is short in treatment course, quick in effect and free of toxic and side effects, and has an excellent curative effect on treating diabetic complications.

The technical scheme of the invention discloses black fungus protein capable of reducing blood glucose and resisting oxidation as well as a preparation method and application of the black fungus protein. The amino acid sequence of the black fungus protein is as shown in SEQ ID NO. 1. The protein which is separated and identified from the black fungus for the first time and has the effects of reducing blood glucose and resisting oxidation achieves the effect of reducing blood glucose through double inhibition of alpha-amylase and alpha-glucosidase, meanwhile, the protein has remarkable antioxidant activity, animal experiments prove that fasting blood glucose and body weight of a type II diabetes model mouse can be effectively reduced, and the protein has a good application prospect. The compound has high biological activity and safety, and can be used for developing functional products with hypoglycemic and antioxidant activity.

Described herein is GLP-1R agonists and pharmaceutical compositions comprising the said compound. The subject compound and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

This invention discloses a traditional Chinese medicine composition for reversing type 2 diabetes and its preparation method, belonging to the field of traditional Chinese medicine technology. It comprises the following raw materials in parts by weight: Astragalus membranaceus 25-35 parts, Rehmannia glutinosa 20-30 parts, Trichosanthes kirilowii 15-25 parts, Anemarrhena asphodeloides 10-20 parts, Coptis chinensis 8-15 parts, Salvia miltiorrhiza 15-25 parts, Ligusticum chuanxiong 8-15 parts, Paeonia lactiflora 10-20 parts, Pueraria lobata 20-30 parts, Atractylodes lancea 10-20 parts, Poria cocos 15-25 parts, Alisma plantago-aquatica 10-20 parts, Ophiopogon japonicus 15-25 parts, Schisandra chinensis 5-15 parts, and Glycyrrhiza uralensis 3-10 parts. This invention strictly follows the principles of traditional Chinese medicine's principal, assistant, adjuvant, and guide herb combination, comprehensively addressing the four methods of invigorating qi and nourishing yin, clearing heat, resolving blood stasis, and eliminating turbidity. It regulates the body's metabolism from the root cause, significantly controlling blood sugar and improving insulin resistance, while also protecting pancreatic function, thus solving the problems of single herb combinations and limited efficacy in traditional Chinese medicine.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

Provided are novel compounds for GIPR, GLP-1R and GCGR. Specifically, provided are GLP-1R / GIPR / GCGR triagonists peptides, and conjugates comprising an Fc fragment and GLP-1R / GIPR / GCGR triagonists peptides. Pharmaceutical compositions comprising these compounds,as well as uses thereof in treating metabolic conditions and disorders, such as diabetes mellitus, type 2 diabetes, obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and non-alcoholic steatohepatitis (NASH) are also provided.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The invention relates to the technical field of biological medicines, in particular to a Chinese wolfberry all-component mixture and application thereof in treatment of diabetes mellitus. The Chinese wolfberry all-component mixture is prepared through the following steps: S1, taking Chinese wolfberry fruits, performing continuous extraction for three times, combining extracting solutions obtained by the three times of extraction, performing filtration, and performing concentration so as to obtain a Chinese wolfberry fruit extract; s2, taking leaf buds, carpopodium and branches of the Chinese wolfberry, performing continuous extraction for three times, combining the three extraction solutions, filtering, and concentrating to obtain a leaf bud / carpopodium / branch extract of the Chinese wolfberry; and S3, mixing the Chinese wolfberry fruit extract obtained in the step S1 with the Chinese wolfberry leaf bud / fruit stem / branch extract obtained in the step S2, filtering, performing graded purification by adopting an ultrafiltration method, intercepting 20-100kDa components, and sterilizing to obtain a Chinese wolfberry all-component mixture. The Chinese wolfberry all-component mixture disclosed by the invention can be used for remarkably reducing a plurality of biochemical index levels such as fasting blood-glucose, glycosylated hemoglobin, triglyceride and extremely low density lipoprotein of a mouse with type 2 diabetes mellitus.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The invention discloses selenoglycoside gligliflozin as well as a preparation method and application thereof. The structural formula of the selenoglycoside gligliflozin disclosed by the invention is shown as a formula (I). The preparation method of the seleno-glucoside gliflozin comprises the following steps: 1, directly carrying out selenium-carbon coupling reaction on peracetyl-protected 1-seleno-glucose in a solvent under the action of alkali and a palladium catalyst to prepare tetra-acetyl-protected seleno-glucoside gliflozin; and step 2, carrying out deacylation on the tetra-acetyl protected seleno-glucoside gliliflozin product to prepare the seleno-glucoside gliliflozin. A biological activity test shows that the selenoglycoside gliliflozin provided by the invention shows low toxicity to cells, high inhibitory activity to SGLT-2 (sodium glucose transporter 2) and beta-glucosidase hydrolysis resistance, so that the selenoglycoside gliliflozin has the potential to be developed into a medicine for treating diabetes mellitus 2. (I)

The present invention relates to a composition comprising: an insulin derivative comprising at least one arylboronic acid or arylboroxol; and methionine, and to the use of the composition in the treatment of diabetes mellitus, including type 1 diabetes mellitus and type 2 diabetes mellitus.

Provided are methods for treating a disorder characterized by elevated blood glucose levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more IgY antibodies to an extracellular glucose binding domain of a sodium-glucose co-transporter SGLT. Also provided are hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen that contains an extracellular glucose binding domain of a sodium-glucose co-transporter SGLT or fraction thereof, and use of the hyperimmunized eggs or hyperimmunized egg products to reduce blood glucose levels in a subject, such as to treat type 2 diabetes. Methods or preparing the hyperimmunized eggs and hyperimmunized egg products are also provided.

The application discloses Bifidobacterium Pseudocatenulatum and application thereof, and the Bifidobacterium Pseudocatenulatum YSBP01CCTCC NO: M 20232067. Experiments prove that the Bifidobacterium Pseudocatenulatum can enhance the antioxidant capacity of Caenorhabditis elegans, prolong the life of the nematode, improve the activity and the reproductive capacity of the nematode, reduce fat accumulation, improve the mitochondrial membrane potential, and delay the aging of the body. The Bifidobacterium Pseudocatenulatum can also significantly inhibit the weight increase of a high-fat-diet mouse, reduce the TG level in serum of the mouse, significantly reduce the fasting blood glucose concentration, and effectively prevent and relieve obesity and type 2 diabetes.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The application belongs to the technical field of medical devices, and particularly relates to a kind of cryoablation catheter and ablation system, the cryoablation catheter includes inner catheter and outer catheter, the outer catheter is coaxially sleeved on the outside of inner catheter, the inner catheter is configured as a multi-lumen structure, further comprising: a plurality of sealing components, a plurality of the sealing components are arranged on the outside of inner catheter;Wherein, in the initial state, a plurality of the sealing components and inner catheter are located in the inside of outer catheter, in the working state, a plurality of the sealing components and intestinal wall form an ablation closed space together. The application guides the cryoablation catheter to the target position through the guide wire, forms the ablation closed space through the cooperation of sealing components and lumen wall, inputs the cryogenic medium into the ablation closed space to freeze and ablate the lumen wall, provides a usable treatment plan for type 2 diabetes, obesity or other lumen lesion patients, and has the advantages of small trauma, less pain for patients, low surgical risk, etc.

The application discloses a type 2 diabetes heart failure risk prediction system and method, and belongs to the technical field of medical diagnosis and risk assessment. The prediction system comprises the following modules: a data and feature engineering module, which is responsible for standardization processing of data and screening of key prediction factors, and obtains a core feature set for machine learning; a model construction and selection module, which uses the core feature set and trains multiple machine learning algorithms in parallel; through cross-validation and comprehensive performance evaluation, the best model is selected as a prediction model; and a model deployment and application module, which converts output results of the prediction model into a clinically usable static nomogram or online tool, and performs visual output. The application predicts by integrating clinical variables and adopting a machine learning algorithm, and provides a static nomogram and a dynamic Web application, realizes heart failure risk assessment without relying on NT-proBNP detection, and can improve the prevention and management efficiency of cardiovascular diseases.

The invention discloses a medicinal and edible composition with an effect of regulating fasting blood-glucose of type 2 diabetes and application of the medicinal and edible composition, and belongs to the field of medicinal and edible nutritional health-care foods. The medicinal and edible dual-purpose composition with the function of regulating and controlling fasting blood glucose of type 2 diabetes mellitus comprises the following components in parts by weight: 7-9 parts of radix puerariae, 3-5 parts of astragalus membranaceus, 2-4 parts of radix ophiopogonis and 1-3 parts of liquorice. Or 7-9 parts of radix puerariae, 3-5 parts of radix asparagi, 3-5 parts of radix rehmanniae and 1-3 parts of liquorice. All the raw materials of the medicinal and edible combined species are medicinal and edible substances, so that the medicinal and edible combined species have the medicinal effects of traditional Chinese medicines, are safer and lower in toxic and side effects, can effectively regulate and control fasting blood-glucose of type 2 diabetes, can remarkably improve liver cell injury, has a better protection effect on the liver, and is suitable for patients with type 2 diabetes to take for a long time.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of the FER1L6 gene in the prevention and treatment of diabetes. In this application, the expression of GLUT4 is increased by inhibiting the expression of FER1L6, thereby improving the related physiological metabolism in diabetic organisms. This physiological metabolism includes glucose uptake, lipid metabolism, and oxidative stress damage. Experimental results show that FER1L6 is highly expressed in type 2 diabetic mice and insulin-resistant HepG2 cells; reducing FER1L6 expression significantly increases GLUT4 expression, ultimately improving lipid metabolism and oxidative stress damage in diabetic mice, while also enhancing cellular glucose uptake. Therefore, it can be concluded that FER1L6 is a good regulatory target for the prevention and treatment of type 2 diabetes based on the GLUT4 pathway. Based on this target, new technical approaches can be provided for the prevention and control of type 2 diabetes.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

This invention provides compounds for treating type 2 diabetes in patients. [Solution] The following GLP-1 agonists (including pharmaceutically acceptable salts and solvates thereof) and pharmaceutical compositions containing the same are provided. JPEG2026076168000258.jpg4691

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

The present invention relates to GLP-1 receptor agonists compounds of Formula I:and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, n, p, A, X, Y and B are as defined herein. The present invention also relates to compositions which comprise a GLP-1 receptor agonist compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating obesity or non-insulin-dependent diabetes mellitus (Type 2 diabetes) comprising administering to a patient a therapeutically effective amount of a compound of the invention.

The present application belongs to the technical field of medical health, and specifically relates to a type 2 diabetes cognitive function decline prediction system and method. The present application can timely find the cognitive function decline trend by real-time monitoring and analyzing the cognitive function impairment of type 2 diabetes patients, thereby providing a scientific basis for clinical diagnosis and treatment. Through accurate image processing and data analysis, the present application can effectively predict the safety boundary of cognitive function decline and provide personalized prevention and intervention measures for patients. In addition, the present application can accurately assess the level of cognitive function decline according to the diffusion tensor of cognitive function impairment, thereby providing an important reference for doctors to develop treatment plans, and ultimately helping to improve the quality of life of type 2 diabetes patients and reduce the risk of cognitive impairment.

The invention relates to the technical field of machine learning medical prediction, in particular to a diabetes-related pancreatic cancer risk prediction method based on a machine learning model and biological age, and the method comprises the steps: constructing a health reference population queue and a type 2 diabetes application verification queue; determining a core index panel through an automatic machine learning process, and training by adopting a regularization survival analysis model to obtain biological age and age acceleration; based on multi-modal features such as age acceleration, predicting a future pancreatic cancer absolute risk probability by using a machine learning competitive risk model, performing risk grade division, calculating an equal-risk age and supporting risk trajectory simulation according to the future pancreatic cancer absolute risk probability; and packaging the model into a risk prediction toolkit with an adaptive calibration function, and outputting a comprehensive risk assessment report. According to the method, the biological age is trained by adopting the pure health queue, so that the interference of the disease state on aging measurement is avoided, and the prediction precision of the pancreatic cancer risk of the type 2 diabetes mellitus population is improved.